Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $7.20 Average Target Price from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $7.20.

A number of research analysts have recently commented on the stock. Stephens boosted their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Guggenheim boosted their target price on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. Zacks Research downgraded Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd.

Pyxis Oncology Stock Up 5.5%

Shares of PYXS opened at $1.53 on Tuesday. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55. The stock has a market cap of $95.26 million, a PE ratio of -0.96 and a beta of 1.45. The business’s 50-day moving average price is $2.48 and its 200-day moving average price is $2.45.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.01. Analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Trading of Pyxis Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Avanza Fonder AB purchased a new position in Pyxis Oncology in the fourth quarter worth $31,000. Jacobs Levy Equity Management Inc. purchased a new stake in Pyxis Oncology during the third quarter valued at about $134,000. Velan Capital Investment Management LP lifted its stake in Pyxis Oncology by 37.5% during the third quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock worth $122,000 after purchasing an additional 15,000 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Pyxis Oncology in the 3rd quarter worth about $749,000. Finally, Bank of America Corp DE boosted its holdings in shares of Pyxis Oncology by 2,690.9% in the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after purchasing an additional 593,853 shares in the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.